Shionogi & Co., Ltd. (SGIOF)

Market Cap	15.02B +7.7%
Revenue (ttm)	3.14B +14.0%
Net Income	1.29B +20.4%
EPS	1.52 +20.3%
Shares Out	n/a
PE Ratio	11.64
Forward PE	n/a
Dividend	0.46 (2.44%)
Ex-Dividend Date	Mar 30, 2026

Volume	1,500
Open	18.88
Previous Close	17.68
Day's Range	18.88 - 18.88
52-Week Range	14.25 - 26.00
Beta	0.03
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2026

About Shionogi &

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothol...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1878
• Employees: 4,955
• Stock Exchange: OTCMKTS
• Ticker Symbol: SGIOF

Financial Performance

In fiscal year 2026, Shionogi &'s revenue was 499.68 billion, an increase of 14.01% compared to the previous year's 438.27 billion. Earnings were 205.16 billion, an increase of 20.37%.

Financial numbers in JPY